GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at ...
Final 72-Week Analyses of Phase 3 HOPE Study Demonstrate Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status Real-World Experience Study Results Consistent with HOPE Study and Show Improved Patient Health Status …